News

Kadans Science Partner is happy to welcome a new member to Plus Ultra Utrecht: QVQ. They are the second tenant to sign a lease for the newest life sciences building currently under development on Utrecht Science Park. QVQ is your one-stop shop for affordable high quality single domain antibodies. Their custom projects are tailored to each customer based on a broad range of services, including llama immunization (in collaboration), construction of phage display libraries, custom-tailored selection procedures, production of VHH, plain or equipped with different tags in bacteria and yeast. The QVQ team strives to use its extensive experience to make single domain antibody technology available to the largest possible user base. Close collaborations with top academic research groups and industrial partners ensure … Read more

On Thursday the 30th of March 2023, our talented early-stage researcher (ESR) within the ITN project ONCORNET2.0, Stephanie Mareike Anbuhl , presented her poster on the reformatting of improved CXCR4-targeting single domain antibodies for biophysical detection methods on the annual meeting of the Medicinal Chemistry & Chemical Biology (MCCB) division of the Royal Netherlands Chemical Society (KNCV) in Lunteren. On her poster, Stephanie illustrated how various immunization and phage display approaches can aid the development of novel CXCR4 binding single domain antibodies against previously untargeted epitopes or conformations and with unprecedented affinity and potency. Also, Stephanie showed examples how such molecules can be developed into higher order multivalent formats for improving potencies even further as well as conjugating them to make … Read more

In a collaborative project, researchers at QVQ (Stephanie Mareike Anbuhl and Raimond Heukers), VU Amsterdam (Martine Smit lab) and University of Nottingham (Laura Kilpatrick and Steve Hill) have developed a novel approach using labeled VHH to easily assess and quantify binding of ligands to different drug targets. This technology, named NanoB2 (nanobody-NanoBRET), was published in the journal of Cell Reports Methods. The work, driven by Jelle van den Bor and Nick Bergkamp proves again the high potential of labeled VHH as detection agents. In this new technology, labeled VHH are used for the determination of the binding sites, kinetics and affinities of unlabeled drugs and thereby aid the identification of novel ligands.  Link

QVQ recently contributed to a study that nicely exemplifies directionally fluorescently labelled single domain antibodies as extracellular receptor conformation sensors. This is a result of a smooth ONCORNET2.0 collaboration, in this case led by Laura Kilpatrick and Steve Hill. Link

Candida albicans is an opportunistic yeast naturally occurring on our body. This yeast can become pathogenic causing candidiasis. Candidalysin, a peptide toxin secreted by the fungus, is involved in Candida becoming pathogenic the  mediates its translocation through intestinal epithelium causing serious infections. A recent study led by prof. Bernard Hube now shows that Candidalysin is also the driver of C. albicans-associated haemolysis. This process can be fully inhibited by two single domain antibodies. Link

Big thanks to the group led by Anne Rios, who did an excellent job with establishing the mLSR-3D method for multispectral confocal 3D imaging. This nicely illustrates the excellent organ penetration of single domain antibodies and its suitability for imaging.

Congrats to the team lead by professor Arjan Griffioen for their excellent study on targeting extracellular vimentin for cancer therapy. Link This study also features our anti-vimentin product Q60c, a single domain antibody that suits well for detection and microscopy. QVQ Product Q60c

More than 1.5 million Dutch people suffer from osteoarthritis – a rheumatic disease of the joints that causes pain, stiffness and difficulty in moving. Since osteoarthritis is a condition that mainly occurs to elderly people, the number of patients will increase due to aging of the population. Currently there is no adequate treatment. The OAinject program is developing new diagnostic tools to determine the exact type of osteoarthritis someone has, in order to enable tailor-made treatments. In addition, the researchers are working on innovative ways to administer medicines in the joints over a longer period of time, gradually, as well as locally via a depot. In this way, the consortium wants to ensure that rheumatic patients can maintain an active … Read more